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Abstract: MicroRNAs (miRNAs) are small noncoding RNAs that modulate the cellular transcriptome
at the post-transcriptional level. miRNA plays important roles in different disease manifestation,
including type 2 diabetes mellitus (T2DM). Many studies have characterized the changes of miRNAs
in T2DM, a complex systematic disease; however, few studies have integrated these findings and
explored the functional effects of the dysregulated miRNAs identified. To investigate the involvement
of miRNAs in T2DM, we obtained and analyzed all relevant studies published prior to 18 October
2016 from various literature databases. From 59 independent studies that met the inclusion criteria,
we identified 158 dysregulated miRNAs in seven different major sample types. To understand the
functional impact of these deregulated miRNAs, we performed targets prediction and pathway
enrichment analysis. Results from our analysis suggested that the altered miRNAs are involved
in the core processes associated with T2DM, such as carbohydrate and lipid metabolisms, insulin
signaling pathway and the adipocytokine signaling pathway. This systematic survey of dysregulated
miRNAs provides molecular insights on the effect of deregulated miRNAs in different tissues during
the development of diabetes. Some of these miRNAs and their mRNA targets may have diagnostic
and/or therapeutic utilities in T2DM.
Keywords: microRNA; type 2 diabetes mellitus; miRNA-mRNA interaction network; systematic study
1. Introduction
Diabetes mellitus has become a global epidemic. It affects roughly 8.3% of the population, with
90% of these patients suffering from type 2 diabetes mellitus (T2DM) [1]. T2DM is a complex disease
caused by both genetic and environmental factors [2]. It often occurs in middle-aged adults with
chronic hyperglycemia. Lifestyle changes are often used to prevent or manage the progression of
the disease. However, the pancreatic β-cell dysfunction usually progresses and results in insulin
resistance and/or relative insulin insufficiency in key metabolic organs, such as skeletal muscle, liver
and adipose tissues [3]. Long-term de-regulation of energy metabolism in T2DM leads to systemic
complications, such as CAD (coronary artery disease), stroke, peripheral arterial disease [4], CKD
(chronic kidney disease) [5], microvascular diseases (retinopathy) [6] and various other conditions,
such as cancers [7–11].
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MicroRNAs (miRNAs) are 17–21 nt regulatory RNAs that suppress the translation and stability
of mRNA through imperfect base pairing in the 3′ untranslated region of its mRNA targets [12].
There are over 2500 human miRNAs deposited in the latest release of miRBase (available online:
www.mirbase.org). It has been estimated that more than 60% of protein coding transcripts are
regulated by one or more miRNAs [13]. A number of dysregulated miRNAs from insulin-sensitive
organs, including skeletal muscle, white adipose tissue and insulin-producing pancreatic β-cells, has
been linked to processes related to diabetes, such as insulin secretion, pancreatic β-cells and adipocyte
differentiation [14]. Systematic studies on the involvement of these aberrant miRNAs in T2DM will
enhance our understanding of the molecular processes involved in the development of T2DM and
facilitate the development of new disease management tools, therapeutic targets, diagnostic markers
and preventive measures for T2DM.
Many studies have characterized the changes and involvement of miRNA in different cell types
and organs during the development of T2DM [15–22]. Due to the complexity of T2DM pathology,
a thorough systematic comparison, integration and investigation on the functional implications
of these dysregulated miRNAs is still needed. We searched all reports related to miRNA and
T2DM, downloaded and analyzed the data that met our inclusion criteria and identified a set of
dysregulated miRNAs from 59 independent studies. Based on their predicted and validated targets,
we conducted pathway enrichment analysis and built mRNA-miRNA interaction networks that help
our understanding of the effects of these aberrantly expressed miRNAs in T2DM. The identified miRNA
meta-signature and perturbed networks associated with T2DM will facilitate our understanding of the
underlying biological processes in the development of T2DM.
2. Results
2.1. Study Characteristics
The schema of data identification and selection is shown in Figure 1. According to the search
criteria outlined, a total of 7329 publications were identified through initial searches of various
databases using different combinations of terms as described in the Materials and Methods section.
During the data extraction step, 2794 duplicated records were removed, and an additional 2664 studies
were also excluded due to either review, meta-analysis, letter, news or editorial articles (n = 405);
thesis or conference reports/abstracts (n = 268); unrelated studies (n = 1973); non-English or Chinese
publications (n = 18). After detailed evaluation, another 71 studies were removed due to not using
human samples (n = 52), being T1DM studies (n = 16) and studies without specify T1 or T2DM (n = 3).
At the end, the results from 59 published studies were retrieved from public databases, which include
a total of 2671 T2DM patients and 2573 healthy controls (Figure 1).
The main characteristics extracted from various datasets are summarized in Table 1, which
includes the number of patients investigated, the measurement platform, type of sample used and the
identity of miRNAs in the study [23–81]. Comparing results from multiple tissues provides an overall
view of the impact of miRNAs in T2DM pathology. Before analysis, we updated the miRNA name
according to the latest nomenclature provided by miRBase. Three miRNAs, miR-463, miR-768 and
miR-801, were removed from analysis due to these miRNAs no longer being recognized as miRNAs.
Several major sample types were involved in the 59 studies, including adipose tissue, islet, skeletal
muscle, whole blood, PBMC (peripheral blood mononuclear cell), serum and plasma. Some miRNAs
showed inconsistent changes among different studies within the same sample type, and these miRNAs
are indicated in Tables 2 and 3. For studies that included profiling, as well as validation components,
we selected validated miRNAs for further study; for example in the study by Karolina et al. [26],
eight qRT-PCR validated differentially expressed miRNAs (miR-29a, -144, -150, -192, -320a, -30d, -146a
and miR-182) identified by microarray profiling results were included in our analysis (Table 1).
Int. J. Mol. Sci. 2017, 18, 456 3 of 23
Table 1. Main characteristics of the reports included in the study.
Author, Year (Ref.) Country Sample Type miRNA ExpChange Assay Method Number of Samples Avg Age Gender (M/F) QC
Ding et al., 2016 [63] China Serum
miR-451a, -4534 Up RT-qPCR T2DM(40)/NC(56) 61.21 59/37 9
miR-320d, -3960, -572 Down
Hou et al., 2016 [62] China Pancreatic islets miR-463-3p Up RT-qPCR T2DM(34)/NC(34) 53 ± 7.5 35/33 7
Jansen et al., 2016 [61] Germany Plasma miR-126, -26a Down RT-qPCR T2DM(55)/NC(80) 66.4 ± 10.9 45/90 7
Latouche et al., 2016 [60] Australia SM miR-194 Down RT-qPCR T2DM(6)/NC(5) 50.72 NA 8
Li et al., 2016 [59] China Serum miR-221/222 Up RT-qPCR T2DM(30)/NC(20) 60.28 NA 7
Pek et al., 2016 [58] China, Malaysia,India and Others Adipose tissue
miR-100, miR-378, miR-99a, miR-125b,
miR-181a, miR-210 and miR-378 Down
Microarray
RT-qPCR T2DM(42)/NC(73) 40.4 ± 11.25 NA 7
Rezk et al., 2016 [57] Egypt Serum miR-126 Down RT-qPCR T2DM(100)/NC(100) 46.95 95/105 9
Seyhan et al., 2016 [56] USA Plasma miR-30d, -34a, -21, -148a Up RT-qPCR T2DM(31)/NC(27) 40.05 30/28 9
Yan et al., 2016 [53] China Plasma
miR-572 Up Microarray
RT-qPCR T2DM(50)/NC(50) 45.87 49/51 8miR-1249, -320b Down
Wang et al., 2016 [55] China Serum miR-661, -571, -770-5p, -892b, -1303, -15a,-16, -125b, -221, -320a Up RT-qPCR T2DM(92)/NC(92) 48.95 114/70 8
Baldeon et al., 2016 [64] Ecuador Serum miR-574-3p, -146a Down RT-PCR T2DM(64)/NC(44) 61 (37–85) 37/71 8
Wang et al., 2016 [54] China Plasma miR-296, -9 Down RT-qPCR T2DM(150)/NC(150) 48.6 ± 1.7 150/150 7
Long et al., 2015 [67] China PBMC miR-223-3p Down RT-qPCR T2DM(16)/NC(18) 55 20/14 6
Olivieri et al., 2015 [66] Italy PBMC miR-126-3p, -21-5p Down RT-qPCR T2DM(76)/NC(107) 64.79 85/98 9
Yang et al., 2015 [52] China Plasma/platelets
miR-144 Up
RT-qPCR T2DM(114)/NC(30) 49.8 ± 9.1 NA 8
miR-223 Down
Higuchi et al., 2015 [70] Japan Serum miR-101, -375, -802 Up RT-qPCR T2DM(155)/NC(49) 62.3 ± 13.2 121/83 7
Al-Kafaji et al., 2015 [73] Bahrain WB miRNA-15a Down RT-qPCR T2DM(24)/NC(24) 52 ± 6.0 23/25 8
Lenin et al., 2015 [68] India PBMC miR-146a Down RT-qPCR T2DM(35)/NC(35) 47.3 ± 7 36/34 6
Sebastiani et al., 2015 [65] Italia Pancreatic islets miR-124a Up RT-qPCR T2DM(5)/NC(10) 71.2 ± 9.8 7/8 7
Jiao et al., 2015 [69] China PB miR-130a, -10b, -143 Down RT-qPCR T2DM(30)/NC(42) 56 ± 10 NA 8
Bao et al., 2015 [71] China Plasma/Serum miR-185 Down RT-qPCR T2DM(34)/NC(30) NA NA 9
Baldeón et al., 2015 [72] Ecuador PBMC miR-34c-5p, -576-3p Up MicroarrayRT-qPCR T2DM(64)/NC(44) 61 (37–85) 37/71 6
Wu et al., 2015 [79] China PBMC miR-21 Up RT-qPCR T2DM(18)/NC(18) 53.6 ± 4.6 18/18 7
Ortega et al., 2014 [77] Spain Plasma
miR-140-5p, -142-3p, -222 Up
RT-qPCR T2DM(48)/NC(45) 54 ± 10 93/0 8miR-423-5p, -125b, -192, -195, -130b,
-532-5p, -126 Down
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Table 1. Cont.
Author, Year (Ref.) Country Sample Type miRNA ExpChange Assay Method Number of Samples Avg Age Gender (M/F) QC
Yan et al., 2014 [80] China Plasma miR-199a Up RT-PCR T2DM(64)/NC(64) 46–62 NA 8
Lu et al., 2014 [76] China Plasma miR-375, miR-126 Up RT-qPCR T2DM(30)/NC(30) 53.67 ± 8.92 42/18 8
Wang et al., 2014 [78] Swedes Iraqis Plasma
miR-15a, -21, -144, -150, -486-5p Up
RT-qPCR T2DM(33)/NC(119) 45-65 83/69 7
miR-24, -29b, -126, -320a Down
Liu et al., 2014 [35] China Serum miR-126 Down qPCR T2DM(160)/NC(138) 50.2 ± 6.7 78/82 9
Pan et al., 2014 [51] China WB miR-146a, -155 Down FQ-PCR T2DM(36)/NC(32) 61.0 ± 7.0 20/16 9
Locke et al., 2014 [36] UK Islet miR-129-3p, -187, -345 Up RT-qPCR T2DM(9)/NC(11) 53 7/2 5
Yang et al., 2014 [40] China Serum miR-23a, let-7i, -486, -96, -186, -191,-192, -146a Down RT-qPCR T2DM(24)/NC(20) 50.60 ± 5.128 16/8 9
Santovito et al., 2014 [38] Germany Plasma
miR-326 Up
RT-qPCR T2DM(18)/NC(12) 57.2 ± 9.6 12/6 7
miR-let-7a,let-7f Down
Mao et al., 2014 [35] China Serum miR-18a Down qPCR T2DM(33)/NC(33) 53.8 (35–72) 13/20 6
Baldeon et al., 2014 [32] Netherlands Serum miR-146a Down RT-qPCR T2DM(56)/NC(40) 62 (38–85) 22/34 8
Sun et al., 2014 [39] China Plasma miR-375 Up qPCR T2DM(100)/NC(100) 51.33 ± 11.75 54/46 9
Kameswaran et al.,
2014 [23] USA Islet
miR-7, -136, -369, -369-3p, -411, -432, -487a,
-487b, -495, -539-3p, -655, -656 Down RT-qPCR T2DM(20)/NC(29) 51.35 (22–65) 14/6 8
miR-187, -187 *, -224, -589 Up
Zhang et al., 2014 [41] China Serum miR-29b Up RT-PCR T2DM(50)/NC(50) 35–70 30/20 8
Ren et al., 2014 [37] China Plasma miR-126 Down RT-PCR T2DM(40)/NC(40) 43.0 ± 11.0 24/16 9
Zhou et al., 2013 [47] China WB let-7a Up RT-PCR T2DM(104)/NC(62) 52.8 ± 10.4 59/45 9
Pescador et al., 2013 [45] Spain Serum miR-503 Down RT-qPCR T2DM(13)/NC(20) 69.40 ± 7.12 7/6 8
Zhang et al., 2013 [47] China Plasma miR-126 Down RT-qPCR T2DM(30)/NC(30) 63 ± 8.56(42–73) 16/14 8
Agarwal et al., 2013 [42] India SM miR-135a Up RT-PCR T2DM(3)/NC(3) 65–75 3/0 5
Rong et al., 2013 [46] China Plasma miR-146a Up qPCR T2DM(90)/NC(90) 48.50 (42–56) 47/43 9
Corral, et al., 2013 [43] México PBMC miR-146a, -155 Down RT-PCR T2DM(20)/NC(20) 46.2 (35–59) 11/9 6
Liang et al, 2013 [75] China Serum miR-29a, -375 Up RT-FQ-PCR T2DM(48)/NC(38) 54.9 ± 9.8(35–72) 27/21 9
Zhou et al., 2012 [81] China Serum miR-181a Up RT-PCR T2DM(20)/NC(20) NA NA 7
Meng et al., 2012 [28] China PBMC miR-21, -27a, -27b, -126, -130a Down MicroarrayRT-qPCR T2DM(15)/NC(15) 67 ± 8 7/8 8
Karolina et al., 2012 [27] Singapore WB
miR-17, -92a, -130a, -195, -197,
-509-5p, -652 Down Microarray
RT-qPCR T2DM(50)/NC(46) 42.02 NA 9miR-27a, -150, -192, -320a, -375 Up
Balasubramanyam et al.,
2011 [24] India PBMC miR-146a Down RT-qPCR T2DM(20)/NC(20) 43.7 ± 5.1 NA 8
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Author, Year (Ref.) Country Sample Type miRNA ExpChange Assay Method Number of Samples Avg Age Gender (M/F) QC
Caporali et al., 2011 [25] U.K.
Plasma miR-503
Up RT-PCR T2DM(10)/NC(11) 68.09 ± 9.06 9/1 7
SM miR-503
Karolina et al., 2011 [26] Singapore WB
miR-15a, -17, -17 *, -23a, -23b, -26a, -26b,
-27a, -29b, -29c, -99b *, -106b, -125a-5p,
-125b, -126, -130a, -130b, -142-3p, -151-3p,
-151-5p, -183, -185, -190, -193a-3p, -194,
-221, -222, -299-3p, -320b, -320c, -320d,
-335, -361-3p, -375, -502-3p, -550, -550 *,
-589, -620, -629, -665, -886-5p, -1285, -1301
Up
Microarray
T2DM(21)/NC(15) 43.2 (21–70) 21/0 9
miR-7, -19a, -20a, -20b, -30c, -30e, -34b,
-106a, -129-5p, -146b-5p, -185 *, -186, -340,
-342-3p, -362-5p, -374b, -519e, -532-3p,
-636, -637, -652, -660, -923, -1184, -1297,
let-7b *, let-7d, let-7e, let-7g, let-7i
Down
miR-29a, -144, -150, -192, -320a Up RT-qPCR
miR-30d, -146a, -182 Down
Kong et al., 2011 [34] China Serum miR-9, -29a, -30d, -34a, -124a, -146a, -375 Up RT-qPCR T2DM(18)/NC(19) 47.33 ± 2.617 9/9 9
Zhao et al., 2010 [31] Hong Kong Pancreas miR-375 Up RT-qPCR T2DM(40)/NC(15) 69 ± 13 17/23 8
Zampetaki et al., 2010 [30] U.K. Plasma
miR-15a, -20b, -21, -24, -29b, -126, -150,
-191, -197, -223, -320, -486 Down Microarray/
RT-qPCR T2DM(80)/NC(80) 66.3 ± 8.9 30/50 5
miR-28-3p Up
Gallagher et al., 2010 [49] U.K. SM
miR-15b, -30b *, -30c-2 *, -32 *, -93, -106b,
-138-1 *, -142-3p, -142-5p, -143, -144,
-181a-2 *, -185, -193a-5p, -371-5p, -451,
-503, -518c *, -589, -597, -600, -634, -658,
-665, -668, -765, -921, -923, -937
Up Microarray
T2DM(45)/NC(47) 54.8 ± 10.2 NA 7miR-10a, -10b, -15a, -27b, -30e, -95, -100,
-126 *, -128, -133a, -152, -154, -190, -196a,
-199a-3p, -199b-5p, -206, -208a, -331-3p,
-342-3p, -362-3p, -374a, -374b, -378 *, -422a,
-423-3p, -424, -455-5p, -519d, -768-3p,
-768-5p, -801
Down
Ortega et al., 2010 [29] Spain Adipose
miR-125b, -199a-5p, -221, -1229 Up
RT-PCR T2DM(9)/NC(6) 45 ± 10 0/9 8
miR-30a *, -130b, -484 Down
Kong et al., 2010 [74] China Serum miR-34a Up RT-qPCR T2DM(18)/NC(26) 47.33 ± 2.62 23/21
Klöting et al., 2009 [50] Germany Adipose
miR-147, -181a, -197 Up
Microarray T2DM(6)/NC(9) 67 ± 2.8 NA 8miR-17-5p, -27a, -30e, -132, -134, -140,
-155, -210 Down
Granjon et al., 2009 [33] France SM miR-1, -133a Down RT-qPCR T2DM(5)/NC(15) 51 ± 2 2/3 7
Abbreviations: T2DM: type 2 diabetes; NC: normal control; NA: not available; PBMC, peripheral blood mononuclear cell; WB: whole blood; SM: skeletal muscle.
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Figure 1. The flow chart of the data selection and identification process.
2.2. Quality Assessment
The quality assessment scores listed in Table 1 were conducted in accordance with the
QUADOMICS tool. None of the studies were classified as “low quality”, fulfilling fewer than 12 of the
16 criteria. Since none of the studies were conducted as blind tests (without knowledge of the reference
standard and patient sample), all studies failed Criteria 12 and 13 of the QUADOMICS tool.
2.3. Alterations of Specific miRNAs’ Levels among Different Tissues in T2DM
From 59 independent reports, a total of 158 dysr gulated miRNAs were identified (Tables 1 and 2).
According to the sample type used, results from most of the studies can be divided into seven major
groups (adipose, islet, skeletal muscle, whole blood, PBMC, plasma and serum).
Skeletal muscle had the most number of affected miRNAs: 29 with decreased concentration and
31 with increased concentration in skeletal muscle samples from T2DM patients compared to healthy
controls (Table 2). As expected, there are more aberrantly-expressed miRNAs in common among whole
blood, PBMC, serum and plasma (Table 3). This is especially true between serum and plasma, since
these are prepared from a common source. Between serum and plasma, there are 16 affected miRNAs
in common; however, the concentration changes between the two may be different. For example,
the levels of miR-191-5p and miR-192-5p are decreased in both serum and plasma in T2DM patients
compared to healthy controls, but the concentration changes of miR-29b-3p and miR-320a are opposite
between serum and plasma (Tables 2 and 3). The concentration of miR-375, a highly enriched miRNA
in pancreatic tissue, is increased in the islet of T2DM patients, as well as in whole blood, serum and
plasma. There are also some common changes between skeletal muscle and whole blood, for example
miR-100-5p, miR-126-3p and miR-144-3p. This suggests some of the deregulated circulating cell-free
miRNAs might reflect T2DM-associated pathologies in different tissues.
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Table 2. List of dysregulated miRNAs identified from seven different types of samples used in T2DM studies.










miR-135a-5p miR-451a miR-148a-3p miR-222-3p
miR-138-1-3p miR-503-5p miR-15a-5p miR-29a-3p
miR-142-3p miR-518c-5p miR-150-5p miR-29b-3p
miR-142-5p miR-589-5p miR-199a-5p miR-30d-5p
miR-143-3p miR-597-5p miR-21-5p miR-320a
miR-144-3p miR-600 miR-222-3p miR-34a-5p
miR-124-3p miR-15b-5p miR-634 let-7a-5p miR-28-3p miR-375
miR-1229-3p miR-129-3p miR-181a-2-3p miR-658 miR-144-3p miR-30d-5p miR-451a
miR-125b-5p miR-187-3p miR-185-5p miR-665 miR-150-5p miR-326 miR-4534
miR-147a miR-187-5p miR-193a-5p miR-668-3p miR-192-5p miR-34a-5p miR-571
miR-181a-5p miR-224-5p miR-30b-3p miR-765 miR-27a-3p miR-375 miR-661
miR-197-3p miR-345-5p miR-30c-2-3p miR-921 miR-29a-3p miR-21-5p miR-486-5p miR-770-5p
miR-199a-5p miR-375 miR-32-3p miR-93-5p miR-320a miR-34c-5p miR-503-5p miR-892b
miR-221-3p miR-589-5p miR-371a-5p miR-937-3p miR-375 miR-576-3p miR-572 miR-9-5p
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Table 2. Cont.
Increased in T2DM Patient a
Adipose b Islet b Skeletal Muscle b Whole Blood b PBMC b Plasma b Serum b
T2DM(72)/NC(103) T2DM(88)/NC(113) T2DM(114)/NC(128) T2DM(378)/NC(312) T2DM(264)/NC(277) T2DM(1058)/NC(1234) T2DM(961)/NC(821)
miR-100-5p miR-136-5p miR-100-5p miR-208a-3p miR-10b-5p miR-126-3p let-7a-5p let-7i-5p
miR-125b-5p miR-369-3p miR-10a-5p miR-27b-3p miR-130a-3p miR-130a-3p let-7f-5p miR-126-3p
miR-130b-3p miR-411-5p miR-10b-5p miR-30e-5p miR-143-3p miR-146a-5p miR-1249-3p miR-146a-5p
miR-132-3p miR-432-5p miR-126-5p miR-331-3p miR-146a-5p miR-155-5p miR-125b-5p miR-186-5p
miR-134-5p miR-487a-3p miR-128-3p miR-342-3p miR-155-5p miR-21-5p miR-126-3p miR-18a-5p
miR-140-5p miR-487b-3p miR-133a-3p miR-362-3p miR-15a-5p miR-223-3p miR-130b-3p miR-191-5p
miR-155-5p miR-495-3p miR-1-3p miR-374a-5p miR-17-5p miR-27a-3p miR-15a-5p miR-192-5p
miR-17-5p miR-539-3p miR-152-3p miR-374b-5p miR-182-5p miR-27b-3p miR-150-5p miR-23a-3p
miR-181a-5p miR-655-3p miR-154-5p miR-378a-5p miR-195-5p miR-191-5p miR-320d
miR-210-3p miR-656-3p miR-15a-5p miR-422a miR-197-3p miR-192-5p miR-3960
miR-27a-3p miR-7-5p miR-190a-5p miR-423-3p miR-30d-5p miR-195-5p miR-486-5p
miR-30a-5p miR-194-5p miR-424-5p miR-509-5p miR-197-3p miR-503-5p
miR-30e-5p miR-196a-5p miR-455-5p miR-652-3p miR-20b-5p miR-572
miR-378a-3p miR-199a-3p miR-519d-3p miR-92a-3p miR-21-5p miR-574-3p











Decreased in T2DM patient a
a miRNAs reported in multiple studies are listed in italic boldface characters, and inconsistent concentration changes between studies from the same sample type are underlined; b the
number of samples involved in patients (T2DM) and controls (NC) is indicated in parentheses under each sample type.
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Table 3. Common changes of miRNAs in different sample types.













miR-144-3p Up Up Up









miR-192-5p Down Down Up
miR-195-5p Down Down











miR-30d-5p Up Up Down
miR-30e-5p Down Down
miR-320a Down Up Up
miR-34a-5p Up Up
miR-375 Up Up Up Up
miR-451a Up Up
miR-486-5p Up DownDown




2.4. Perturbed Pathways Mediated by Dysregulated miRNAs
Using the list of dysregulated miRNAs in each sample type identified from the literature, we
performed pathway enrichment analysis based on validated and predicted miRNA targets (Table S1).
Some of these pathways are known to be involved in T2DM; for example, various pathways associated
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with metabolic processes (carbohydrate and lipid metabolism), cell-cell communications (focal adhesion,
tight junction), cell growth and death (apoptosis and cell cycle), signal transduction (JAK-STAT, MAPK,
TGF-β, Wnt, cytokine-cytokine receptor interaction and neurotrophin signaling), immune response
(leukocyte transendothelial migration, T-cell receptor signaling, Nod-like receptor signaling, Toll-like
receptor signaling and chemokine signaling), insulin signaling and type 2 diabetes signaling.
Based on the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway map and affected
miRNAs from each sample type, we constructed miRNA-mRNA interaction networks for three
key T2DM-associated pathways, T2DM signaling, insulin signaling and adipocytokine pathways
in pancreatic islet (Figure 2) and adipose tissues (Figure 3), to better illustrate the complex interactions
between mRNAs and affected miRNAs in key tissues associated with the manifestation of T2DM.
Since adipose tissue is one of the key organs involved in the development of T2DM, we included
the expression level changes of protein coding mRNAs involved in the pathways from a visceral
adipose tissue expression profiling dataset obtained from the public domain (GSE16415, available
online: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16415). The dataset compared
adipose tissues gene expression differences between women with type 2 diabetes with age and BMI
matched normal women. The omental biopsies samples were from five diabetic and five control
females undergoing cholecystectomy. All subjects used in the study were older than 50 years with BMI
values greater than 30. In both pancreatic islet and adipose tissues, the dysregulated miRNAs target
several well-known T2DM-associated genes. For example, the adiponectin receptor 2 (ADIPOR2) in
the adipocytokine pathway is targeted by miR-375 and miR-136-5p in pancreatic islet and miR-146a in
adipose tissues. The key enzymes in lipid biosynthesis and fatty acid degradation, acyl-coA synthetase
long-chain family members (ACSL1, 2, 3 and 4), are also targeted by multiple miRNAs, including
miR-17-5p, -130b-3p, -134-5p and -181a-5p in adipose tissue and miR-7-5p, -369-3p, -495-3p and -655-3p
in islets.
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Figure 2. Schematic diagram of the microRNA-mRNA interaction networks in pancreatic islets.  
The networks are built based on the KEGG pathway map: T2DM pathway (KEGG hsa04930) (A); 
adipocytokine pathway (KEGG hsa04920) (B); and insulin signaling pathway (KEGG hsa04910) (C). 
The genes are indicated by circles and miRNAs by squares. For detailed descriptions of node shape, 
edge size, edge color and arrow shapes see inserted legend under (A). The predicted 
miRNA-mRNA interactions are indicated by light blue lines, and the thick blue lines indicate 
validated miRNA-mRNA interactions. Interactions denoted in KEGG pathways were presented as 
black solid or dotted lines indicating direct or indirect interactions, respectively. The identity of 
genes and miRNAs involved in the process are listed, and the colors indicate the expression level 
changes in T2DM islets compared to the control; red indicates a higher level in patients; and green 
represents lower levels compared to the control. 
Figure 2. Schematic diagram of the microRNA-mRNA interaction networks in pancreatic islets.
The networks are built based on the KEGG pathway map: T2DM pathway (KEGG hsa04930) (A);
adipocytokine pathway (KEGG hsa04920) (B); and insulin signaling pathway (KEGG hsa04910) (C).
The genes are indicated by circles and miRNAs by squares. For detailed descriptions of node shape,
edge size, edge color and arrow shapes see inserted legend under (A). The predicted miRNA-mRNA
interactions are indicated by light blue lines, and the thick blue lines indicate validat d miRNA-mRNA
interaction . Inte actions denoted in KEGG pathways were prese ted as black solid or do ted lines
indicating direct or indirect interactions, respectively. The identity of genes and miRNAs involved in
the process are listed, and the colors indicate the expression level changes in T2DM islets compared
to the control; red indicates a higher level in patients; and green represents lower levels compared to
the control.
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tissues. The other example is the association between various cardiovascular disease processes and 
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with the onset of T2DM [82]. Our analysis also shows that a number of aberrant miRNAs are 
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involved in both insulin secretion, release and glucose homeostasis [39,87]. Increased miR-375 levels 
in the islets inhibit PDPK1 (3-phosphoinositide-dependent protein kinase 1) expression [31], an 
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Figure 3. Schematic diagram of the microRNA-mRNA interaction networks in adipose tissue.
The networks are built based on the KEGG pathway map: T2DM pathway (KEGG hsa04930) (A);
adipocytokine pathway (KEGG hsa04920) (B); and insulin signaling pathway (KEGG hsa04910) (C).
The genes are indicated by circles and miRNAs by squares. See the legend of Figure 2A for descriptions
of node shape, edge size, edge color and arrow shapes. The identity of genes and miRNAs involved
in the process are listed, and the colors indicate the relative expression changes in T2DM adipose
tissues compared to the control; red indicates higher level in patients; and green represents lower levels
compared to the control. The mRNA expression levels were obtained from GSE16415 (available online:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16415).
3. Discussion
Even though the etiology of T2DM is yet to be fully understood, insulin resistance and pancreatic
β-cell dysfunction are the two major causes for various T2DM-associated clinical phenotypes [3],
and these conditions usually occur years before the clinical diagnosis of T2DM [82]. Many studies
have suggested that miRNA is one of the key players in the pathogenesis of T2DM and associated
complications, such as cardiovascular conditions and kidney dysfunction [83–85]. The current
analysis identified 158 T2DM-associated dysregulated miRNAs in seven different sample types.
Pathway enrichment analysis revealed that a number of T2DM relevant pathways is targeted by
these dysregulated miRNAs. For example, the disturbed insulin signaling pathway might be one of
the key reasons for the glucose and lipid metabolism impairments, which cause insulin insufficiency
in skeletal muscle, liver and adipose tissues [86]. The other interesting finding is the observation that
some kidney and cardiovascular function-related pathways were also affected by these dysregulated
miRNAs (Table S1). For example, the vasopressin-regulated water reabsorption pathway is enriched
in genes that are targeted by dysregulated miRNAs in adipose tissues. The other example is the
association between various cardiovascular disease processes and dysregulated miRNAs in serum.
It is well-known that hyperglycemia, hyperlipidemia and islet β cell dysfunction are associated
with the onset of T2DM [82]. Our analysis also shows that a number of aberrant miRNAs are
involved in pathways associated with energy metabolism, insulin signaling, type 2 diabetes signaling
and adipocytokine signaling (Table S1). Among the 19 dysregulated miRNAs in pancreatic islets,
miR-375 is probably the best characterized miRNA that has been shown to be involved in both insulin
secretion, release and glucose homeostasis [39,87]. Increased miR-375 levels in the islets inhibit PDPK1
(3-phosphoinositide-dependent protein kinase 1) expression [31], an important component of the
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PI3k/protein kinase B signal cascade (Figure 2B, insulin signaling pathway). Loss of PDPK1 in β cells
results in progressive hyperglycemia due to reductions in the number and size of β cells, as well as
defective β cell function [88]. In addition to miR-375, other dysregulated miRNAs in the islets (such as
miR-7-5p, -369-5p, -129-3p,-136-5p, -187-3p, -589-5p, -224-5p, -655-3p, -495-3p) affect the expression of
IRS1, IRS2, AKT1, PPARA, MAPK9, MAPK10, STAT3, PPKAG2, ACSL3 and ACSL4, which are important
genes involved in insulin signaling and type 2 diabetes pathways [89,90] (Figure 2A–C), and have been
implicated in various events associated with islet β cell development and glucose-stimulated insulin
secretion (GSIS) [23,36,90,91].
Adipose tissues play a key role in maintaining the homeostasis of the body’s energy metabolism
by releasing an array of hormones and cytokines: adipocytokines. The current study revealed that the
dysregulated miRNAs play important roles in glucose, as well as lipid metabolism (Table S1) [29,50,92].
These miRNAs, including miR-17-5p, -155-5p, -125b-5p, -30e-5p, -27a-5p, -221-3p, -199a-5p, -130b-3p,
-181a-5p, -29a, -29b, interact with multiple transcription factors, such as PPARs (peroxisome proliferator
activated receptors), including PPARG, also known as PPARγ, and adipocyte-enriched genes (GLUT4
(also known as SLC2A4), SOCS1, SOCS3, GRB2, INSR and PPARG), to regulate many aspects of
the lipid and glucose metabolisms [90,93]. Some of these miRNAs (miR-130b-3p, -140-5p, -147a,
-199a-5p, -27b, -221-3p and -30e-5p) have also been implicated in the regulation of adipogenesis through
PPARG [94,95]. miR-181a-5p, -132-3p, -199a-5p, -24-3p and -126-3p also contribute to an increased
glucose uptake by affecting PI3K/AKT activity, where the PI3K/ATK signaling is essential for SLC2A4
(GLUT4) translocation to the cell membrane. In addition, miR-130b-3p, -132-3p, -181a-5p, -199a-5p
and -221-3p can directly target PPKAs (AMP-activated protein kinase) to affect energy metabolism in
various signal transduction pathways, including adipocytokine and insulin signaling pathways [90,93]
(Figure 3A–C). Dysfunction of adipose tissues may induce inflammation and insulin resistance by
releasing pro-inflammatory cytokines, such as TNFA (tumor necrosis factor alpha) and IL-6 (interleukin
6), as well as energy regulating hormones including LEP (leptin), ADIPOQ (adiponectin), RETN
(resistin) and ITLN1 (intelectin 1) [96]. The aberrant expression of these genes/proteins will further
the manifestation of T2DM.
Skeletal muscle is one of the main tissues involved in glucose uptake and metabolism. Insulin
resistance in skeletal muscle is an early sign of T2DM and is a risk factor for cardiovascular diseases
common among patients with T2DM [49,86]. Studies have indicated that several miRNAs (miR-17-5p,
-24, -126, -125b-5p, -130b-3p, -132-3p, -181a-3p, -181a-5p, -197-3p and -221-3p) can target and affect
MAPK protein (mitogen-activated protein kinases) levels under high glucose condition [49,97,98].
MAPKs can then affect the level of MEF2 (myocyte enhancer factor 2), which is a key muscle-specific
transcription factor to regulate the transcription of the insulin-responsive SLC2As (solute carrier
family 2 transporters, which facilitate glucose transport), including GLUT4 (glucose transporter 4,
SLC2A4) [49,93].
There are a number of studies investigating the relationship of miRNA and diabetes based on
animal models and cell line systems [99–103]. These studies provide valuable information, but in
the current analysis, we did not include these studies because the model systems, either in vivo
or in vitro, can only reflect very limited aspects of the T2DM pathology. The physiopathological
difference between human and model organisms will also generate a very different set of dysregulated
genes and miRNAs [104,105]. Moreover, even the same miRNA may interact with very different
sets of targets due to a difference in both mRNA and miRNA sequences between human and animal
models. For example, miR-375 has an identical mature sequence between human (hsa-miR-375) and
mouse (mmu-miR-375), but the peroxisome proliferative activated receptor, gamma, coactivator 1
alpha (PPARGC1A), a transcriptional coactivator, interacts with PPARgamma (PPARG) to regulate
genes involved in energy metabolism and is a target of mouse miR-375, but not human. Therefore, in
the current study, we only selected studies from human patient samples in order to investigate the
functional involvement of miRNAs in human T2DM pathology. These findings may provide a more
accurate and more realistic view of the effect of miRNAs in diabetes.
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Some of the miRNA-mRNA interactions in Figures 2 and 3 are based on results from various
miRNA target prediction programs. We used miRSystem, an integrated miRNA function prediction
website based on multiple miRNA target prediction algorithms, to facilitate the summarization of
miRNA-mRNA interaction [106]. There are other similar websites, such as miRGator (available online:
www.mirgator.kobic.re.kr/) [107] and miRPathDB (available online: mpd.bioinf.uni-sb.de/) [108].
All of these tools provide a similar function and deliver comparable results.
In the past few years, there have been a number of reports revealing disease-associated
concentration changes of specific miRNA in circulation, such as miR-375 in patients with T2DM
(Table 3) [31,34,39,75]. However, the idea of using circulating miRNA to reflect pathological changes
in specific tissues and/or as a reliable biomarker for disease diagnosis faces numerous challenges.
These difficulties are due to many issues, including the accuracy and consistency of different miRNA
measurement platforms, low concentration of circulating RNA in samples and the high sequence
similarity of miRNA family members. However, the biggest challenge of circulating RNA-based
biomarker discovery probably is due to the fact that the spectrum of circulating RNA is the sum of
many different tissues and cell types in the body. How to identify changes from specific tissues or
disease stages from very complex and noisy data is difficult. Using tissue or disease-enriched RNAs
(miRNAs or mRNAs), like miR-375, which is enriched in pancreatic tissue, may provide a useful
approach for circulating RNA-based biomarker discovery. In addition, using animal models that allow
frequent and detailed monitoring of disease-associated RNA profile changes in tissue and body fluid
samples may also provide insights on the relationship of RNA between the two compartments.
In conclusion, we present a systematic analysis by integrating various T2DM-related miRNA
datasets from the literature. These dysregulated miRNAs affect various metabolic and signal
transduction pathways associated with T2DM and may play important roles in the development
of diabetes. The pathway analysis results also provide possible links to kidney and cardiovascular
complications associated the T2DM. However, many other factors, both endogenous and exogenous,
may influence the spectrum of miRNA in tissues and circulation. Recent findings suggest that diet, a
key component in T2DM disease management, affects the spectra of miRNA in various tissues [109,110].
For example, the consumption of milk resulted in significant increases of miRNA levels in plasma
and PBMCs [111]. These findings suggested that individual’s diet and nutritional status can influence
miRNA in tissues and circulation. Therefore, more studies with larger and well-defined populations
are clearly needed to resolve this complex miRNA-mediated regulatory network. The dysregulated
miRNAs and their interacting mRNA targets may provide new insights to the T2DM pathology and
provide new disease monitoring and management tools.
4. Materials and Methods
4.1. Search Strategy and Eligibility of Relevant Studies
We scanned all relevant studies published prior to 18 October 2016 through a comprehensive search
of records in PubMed, The Cochrane Library, the Chinese National Knowledge Infrastructure (CNKI)
database (available online: http://www.cnki.net), Wanfang database (available online: http://www.
wanfangdata.com), VIP database (VIP information/Chinese Scientific Journals database, available online:
http://www.cqvip.com) and Google Scholar. The search was conducted by using combinations of
the following key words: “miRNA” or “microRNA” and “diabetes” or “type 2 diabetes”. The online
search was accompanied by checking cited references from the articles for potentially eligible reports.
References of identified studies that met the inclusion criteria have been assessed by two independent
reviewers. To ensure that relevant studies were not missed, searches in Gene Expression Omnibus
(GEO, available online: www.ncbi.nlm.nih.gov/geo/) and Array Express (available online: www.ebi.
ac.uk/arrayexpress) repositories were also performed.
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4.2. Inclusion and Exclusion Criteria
All miRNA studies associated with T2DM were included in the current meta-analysis if they met
all of the following criteria: (1) full text of original experimental articles based on miRNA expression
profiling between diabetic patients and normal individuals; (2) studies based on human samples;
and (3) original articles published in a language of either English or Chinese. The main exclusion
criteria were as follows: (1) meta-analyses, series, abstract, commentary, review, letters and editorial;
(2) duplicate data; (3) studies that compared different stages of diabetes, but did not include normal
samples; and (4) studies based on cell lines or animal models.
4.3. Data Extraction
Data were extracted by two independent reviewers from all publications that met the inclusion
criteria. The lists of miRNAs with statistically-significant expression changes were extracted from the
publications. All miRNA names were standardized according to miRBase Version 21 (Tables 1 and 2).
Any discrepancies were resolved by consensus or in consultation with a third reviewer. Information
extracted from eligible publications includes: first author’s last name, year of publication, country of
origin, population ethnicity, disease type, measurement platform, source of cases and control groups,
number of samples and number of miRNAs measured. All relevant information was compiled in
Table 1.
4.4. Quality Assessment and Statistical Analysis
We assessed the quality of the data using the QUADAS2 (Quality Assessment of Diagnostic
Accuracy Studies 2) checklist. The categories in the scoring system used for assessing study quality are
summarized in Table 1. Quality scores ranged from 0–10, and studies were scored as “good” if the
score was 8–10, “fair” if the score was 5–7 and “poor” if the score was <4. The dysregulated miRNAs
were grouped into seven groups based on the different sample sources used in the studies (adipose,
islet, skeletal muscle, whole blood, PBMC, plasma, serum).
4.5. miRNA Target Prediction and Pathway Enrichment Analysis
To identify the functional involvement of miRNAs in the progression of T2DM, we used miRNA
target prediction algorithms and information from validated miRNA target databases to generate
the list of putative miRNA targets. The list of putative interacting targets for the miRNAs was
generated using the miRSystem (available online: http://mirsystem.cgm.ntu.edu.tw/index.php) web
server, which provides information from seven miRNA target prediction algorithms, DIANA-microT,
miRanda, mirBridge, PicTar, PITA, RNA22 and TargetScan, and two experimentally-validated miRNA
target databases, TarBase and miRecords [106]. To increase the reliability of target prediction, the targets
that have been predicted by more than 5 different algorithms were then used for pathway enrichment
analysis (available online: http://david.abcc.ncifcrf.gov/home.jsp). Cytoscape (available online:
http://www.cytoscape.org/) and KEGG pathway maps (available online: http://www.genome.jp/
kegg/pathway.html) were used to generate miRNA-mRNA interaction networks. We also included
the mRNA expression level changes from visceral adipose tissue expression profiling data from the
public domain (GSE16415).
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/3/456/s1.
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Abbreviations
GSIS glucose-stimulated insulin secretion
PDPK1 3-phosphoinositide dependent protein kinase 1
PPARG peroxisome proliferator-activated receptor gamma
MAPK mitogen-activated protein kinase
ADIPOR2 adiponectin receptor 2
ACSL acyl-coA synthetase long-chain family members
TNFA tumor necrosis factor alpha
SLC2As solute carrier family 2, which facilitates glucose transport
PPKAs AMP-activated protein kinase
MEF2 myocyte enhancer factor 2
T2DM type 2 diabetes mellitus
miRNA microRNA
References
1. Rogers, E.A.; Fine, S.; Handley, M.A.; Davis, H.; Kass, J.; Schillinger, D. Development and early
implementation of the bigger picture, a youth-targeted public health literacy campaign to prevent type 2
diabetes. J. Health Commun. 2014, 19, 144–160. [CrossRef] [PubMed]
2. Jin, W.; Patti, M. Genetic determinants and molecular pathways in the pathogenesis of type 2 diabetes.
Clin. Sci. 2009, 116, 99–111. [CrossRef] [PubMed]
3. Ribbing, J.; Hamrén, B.; Svensson, M.K.; Karlsson, M.O. A model for glucose, insulin, and β-cell dynamics
in subjects with insulin resistance and patients with type 2 diabetes. J. Clin. Pharmacol. 2010, 50, 861–872.
[CrossRef] [PubMed]
4. Pedicino, D.; Liuzzo, G.; Trotta, F.; Giglio, A.F.; Giubilato, S.; Martini, F.; Zaccardi, F.; Scavone, G.;
Previtero, M.; Massaro, G. Adaptive immunity, inflammation, and cardiovascular complications in type 1
and type 2 diabetes mellitus. J. Diabetes Res. 2013, 2013, 184258. [CrossRef] [PubMed]
5. Bello, N.A.; Pfeffer, M.A.; Skali, H.; McGill, J.B.; Rossert, J.; Olson, K.A.; Weinrauch, L.; Cooper, M.E.; de
Zeeuw, D.; Rossing, P. Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic
kidney disease, and anemia. BMJ Open Diabetes Res. Care 2014, 2, e000011. [CrossRef] [PubMed]
6. Paneni, F.; Beckman, J.A.; Creager, M.A.; Cosentino, F. Diabetes and vascular disease: Pathophysiology,
clinical consequences, and medical therapy: Part I. Eur. Heart J. 2013, 34, 2436–2443. [CrossRef] [PubMed]
7. Shlomai, G.; Neel, B.; LeRoith, D.; Gallagher, E.J. Type 2 diabetes mellitus and cancer: The role of
pharmacotherapy. J. Clin. Oncol. 2016, 34, 4261–4269. [PubMed]
8. Klil-Drori, A.J.; Azoulay, L.; Pollak, M.N. Cancer, obesity, diabetes, and antidiabetic drugs: Is the fog clearing?
Nat. Rev. Clin. Oncol. 2017, 14, 85–99. [CrossRef] [PubMed]
9. Liu, H.T.; Xu, Y.T.; Li, H.Y.; Zhao, J.; Zhai, H.Y.; Chen, Y. Loss of microRNA-145 expression is involved in the
development and prognosis of breast cancer complicated by type 2 diabetes mellitus. Int. J. Biol. Markers
2016, 31, e368–e374. [CrossRef] [PubMed]
10. Wang, Y.; Wang, B.; Yan, S.; Shen, F.; Cao, H.; Fan, J.; Zhang, R.; Gu, J. Type 2 diabetes and gender differences in
liver cancer by considering different confounding factors: A meta-analysis of cohort studies. Ann. Epidemiol.
2016, 26, 764–772. [CrossRef] [PubMed]
11. Sayyid, R.K.; Fleshner, N.E. Diabetes mellitus type 2: A driving force for urological complications.
Trends Endocrinol. Metab. 2016, 27, 249–261. [CrossRef] [PubMed]
12. Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet. 2011, 12, 861–874. [CrossRef] [PubMed]
13. Kellis, M.; Wold, B.; Snyder, M.P.; Bernstein, B.E.; Kundaje, A.; Marinov, G.K.; Ward, L.D.; Birney, E.;
Crawford, G.E.; Dekker, J. Defining functional DNA elements in the human genome. Proc. Natl. Acad.
Sci. USA 2014, 111, 6131–6138. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 456 18 of 23
14. Eliasson, L.; Esguerra, J.L.S. Role of non-coding RNAs in pancreatic β-cell development and physiology.
Acta Physiol. 2014, 211, 273–284. [CrossRef] [PubMed]
15. Lee, M.J.; Park, D.H.; Kang, J.H. Exosomes as the source of biomarkers of metabolic diseases. Ann. Pediatr.
Endocrinol. Metab. 2016, 21, 119–125. [CrossRef] [PubMed]
16. Simpson, K.; Wonnacott, A.; Fraser, D.J.; Bowen, T. MicroRNAs in diabetic nephropathy: From biomarkers
to therapy. Curr. Diabetes Rep. 2016, 16, 35. [CrossRef] [PubMed]
17. Deiuliis, J.A. MicroRNAs as regulators of metabolic disease: Pathophysiologic significance and emerging
role as biomarkers and therapeutics. Int. J. Obes. 2016, 40, 88–101. [CrossRef] [PubMed]
18. Kato, M.; Natarajan, R. MicroRNAs in diabetic nephropathy: Functions, biomarkers, and therapeutic targets.
Ann. N. Y. Acad. Sci. 2015, 1353, 72–88. [CrossRef] [PubMed]
19. Price, N.L.; Ramirez, C.M.; Fernandez-Hernando, C. Relevance of microRNA in metabolic diseases. Crit. Rev.
Clin. Lab. Sci. 2014, 51, 305–320. [CrossRef] [PubMed]
20. Chen, H.; Lan, H.Y.; Roukos, D.H.; Cho, W.C. Application of microRNAs in diabetes mellitus. J. Endocrinol.
2014, 222, 1–10. [CrossRef] [PubMed]
21. Fernandez-Hernando, C.; Ramirez, C.M.; Goedeke, L.; Suarez, Y. MicroRNAs in metabolic disease.
Arterioscler. Thromb. Vasc. Biol. 2013, 33, 178–185. [CrossRef] [PubMed]
22. Guay, C.; Roggli, E.; Nesca, V.; Jacovetti, C.; Regazzi, R. Diabetes mellitus, a microRNA-related disease?
Transl. Res. 2011, 157, 253–264. [CrossRef] [PubMed]
23. Kameswaran, V.; Bramswig, N.C.; McKenna, L.B.; Penn, M.; Schug, J.; Hand, N.J.; Chen, Y.; Choi, I.;
Vourekas, A.; Won, K.-J. Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2
diabetic islets. Cell Metab. 2014, 19, 135–145. [CrossRef] [PubMed]
24. Balasubramanyam, M.; Aravind, S.; Gokulakrishnan, K.; Prabu, P.; Sathishkumar, C.; Ranjani, H.; Mohan, V.
Impaired miR-146a expression links subclinical inflammation and insulin resistance in type 2 diabetes.
Mol. Cell. Biochem. 2011, 351, 197–205. [CrossRef] [PubMed]
25. Caporali, A.; Meloni, M.; Vollenkle, C.; Bonci, D.; Sala-Newby, G.B.; Addis, R.; Spinetti, G.; Losa, S.;
Masson, R.; Baker, A.H.; et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced
impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011, 123,
282–291. [CrossRef] [PubMed]
26. Karolina, D.S.; Armugam, A.; Tavintharan, S.; Wong, M.T.; Lim, S.C.; Sum, C.F.; Jeyaseelan, K. MicroRNA
144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes
mellitus. PLoS ONE 2011, 6, e22839. [CrossRef]
27. Karolina, D.S.; Tavintharan, S.; Armugam, A.; Sepramaniam, S.; Pek, S.L.; Wong, M.T.; Lim, S.C.; Sum, C.F.;
Jeyaseelan, K. Circulating miRNA profiles in patients with metabolic syndrome. J. Clin. Endocrinol. Metab.
2012, 97, E2271–E2276. [CrossRef] [PubMed]
28. Meng, S.; Cao, J.T.; Zhang, B.; Zhou, Q.; Shen, C.X.; Wang, C.Q. Downregulation of microRNA-126 in
endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene
Spred-1. J. Mol. Cell. Cardiol. 2012, 53, 64–72. [CrossRef] [PubMed]
29. Ortega, F.J.; Moreno-Navarrete, J.M.; Pardo, G.; Sabater, M.; Hummel, M.; Ferrer, A.; Rodriguez-Hermosa, J.I.;
Ruiz, B.; Ricart, W.; Peral, B. MiRNA expression profile of human subcutaneous adipose and during
adipocyte differentiation. PLoS ONE 2010, 5, e9022. [CrossRef] [PubMed]
30. Zampetaki, A.; Kiechl, S.; Drozdov, I.; Willeit, P.; Mayr, U.; Prokopi, M.; Mayr, A.; Weger, S.; Oberhollenzer, F.;
Bonora, E.; et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in
type 2 diabetes. Circul. Res. 2010, 107, 810–817. [CrossRef] [PubMed]
31. Zhao, H.; Guan, J.; Lee, H.-M.; Sui, Y.; He, L.; Siu, J.J.; Patty, P.; Tong, P.C.; Lai, F.M.; Chan, J.C. Up-regulated
pancreatic tissue microRNA-375 associates with human type 2 diabetes through β-cell deficit and islet
amyloid deposition. Pancreas 2010, 39, 843–846. [CrossRef] [PubMed]
32. Baldeon Rojas, L.; Weigelt, K.; de Wit, H.; Ozcan, B.; van Oudenaren, A.; Sempertegui, F.; Sijbrands, E.;
Grosse, L.; Freire, W.; Drexhage, H.A.; et al. Decreased serum level of miR-146a as sign of chronic
inflammation in type 2 diabetic patients. PLoS ONE 2014, 9, e115209.
33. Granjon, A.; Gustin, M.P.; Rieusset, J.; Lefai, E.; Meugnier, E.; Guller, I.; Cerutti, C.; Paultre, C.; Disse, E.;
Rabasa-Lhoret, R.; et al. The microRNA signature in response to insulin reveals its implication in the
transcriptional action of insulin in human skeletal muscle and the role of a sterol regulatory element-binding
protein-1C/myocyte enhancer factor 2C pathway. Diabetes 2009, 58, 2555–2564. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 456 19 of 23
34. Kong, L.; Zhu, J.; Han, W.; Jiang, X.; Xu, M.; Zhao, Y.; Dong, Q.; Pang, Z.; Guan, Q.; Gao, L.; et al. Significance
of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol.
2011, 48, 61–69. [CrossRef] [PubMed]
35. Mao, G.; Liu, L. MicroRNA-18a is a genetic marker for the early diagnosis of cerebral injury induced by type
2 diabetes. Exp. Ther. Med. 2014, 8, 1901–1905. [CrossRef] [PubMed]
36. Locke, J.; da Silva Xavier, G.; Dawe, H.; Rutter, G.; Harries, L. Increased expression of miR-187 in human
islets from individuals with type 2 diabetes is associated with reduced glucose-stimulated insulin secretion.
Diabetologia 2014, 57, 122–128. [CrossRef] [PubMed]
37. Ren, Y.H.; Shi, X.X.; Yan, D.D.; Li, X.L. The change of expression level of circulating miRNA-126 in patients
with type 2 diabetes and its relative factors. Clin. J. Diabetes 2014, 22, 633–636.
38. Santovito, D.; De Nardis, V.; Marcantonio, P.; Mandolini, C.; Paganelli, C.; Vitale, E.; Buttitta, F.; Bucci, M.;
Mezzetti, A.; Consoli, A.; et al. Plasma exosome microRNA profiling unravels a new potential modulator of
adiponectin pathway in diabetes: Effect of glycemic control. J. Clin. Endocrinol. Metab. 2014, 99, 1681–1685.
[CrossRef] [PubMed]
39. Sun, K.; Chang, X.; Yin, L.; Li, J.; Zhou, T.; Zhang, C.; Chen, X. Expression and DNA methylation status
of microRNA-375 in patients with type 2 diabetes mellitus. Mol. Med. Rep. 2014, 9, 967–972. [CrossRef]
[PubMed]
40. Yang, Z.; Chen, H.; Si, H.; Li, X.; Ding, X.; Sheng, Q.; Chen, P.; Zhang, H. Serum miR-23a, a potential
biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol. 2014, 51, 823–831. [CrossRef]
[PubMed]
41. Zhang, L.Q.; Han, Z.P. Expression and clinical significance of peripheral hsa-miR-29b during the type 2
diabetes. J. Mod. Lab. Med. 2014, 29, 113–116.
42. Agarwal, P.; Srivastava, R.; Srivastava, A.K.; Ali, S.; Datta, M. MiR-135a targets IRS2 and regulates insulin
signaling and glucose uptake in the diabetic gastrocnemius skeletal muscle. Biochim. Biophys. Acta 2013,
1832, 1294–1303. [CrossRef] [PubMed]
43. Corral-Fernandez, N.E.; Salgado-Bustamante, M.; Martinez-Leija, M.E.; Cortez-Espinosa, N.;
Garcia-Hernandez, M.H.; Reynaga-Hernandez, E.; Quezada-Calvillo, R.; Portales-Perez, D.P. Dysregulated
miR-155 expression in peripheral blood mononuclear cells from patients with type 2 diabetes. Exp. Clin.
Endocrinol. Diabetes 2013, 121, 347–353. [CrossRef] [PubMed]
44. Jiang, S.Y.; Jiao, J.; Zhang, T.T.; Xu, Y.P. Pharmacokinetics study of recombinant hirudin in the plasma of
rats using chromogenic substrate, ELISA, and radioisotope assays. PLoS ONE 2013, 8, e64336. [CrossRef]
[PubMed]
45. Pescador, N.; Perez-Barba, M.; Ibarra, J.M.; Corbaton, A.; Martinez-Larrad, M.T.; Serrano-Rios, M. Serum
circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PLoS
ONE 2013, 8, e77251. [CrossRef] [PubMed]
46. Rong, Y.; Bao, W.; Shan, Z.; Liu, J.; Yu, X.; Xia, S.; Gao, H.; Wang, X.; Yao, P.; Hu, F.B.; et al. Increased
microRNA-146a levels in plasma of patients with newly diagnosed type 2 diabetes mellitus. PLoS ONE 2013,
8, e73272. [CrossRef] [PubMed]
47. Zhou, J.; Peng, R.; Li, T.; Luo, X.; Peng, H.; Zha, H.; Yin, P.; Wen, L.; Zhang, Z. A potentially functional
polymorphism in the regulatory region of let-7a-2 is associated with an increased risk for diabetic
nephropathy. Gene 2013, 527, 456–461. [CrossRef] [PubMed]
48. Liu, Y.; Gao, G.; Yang, C.; Zhou, K.; Shen, B.; Liang, H.; Jiang, X. The role of circulating microRNA-126
(miR-126): A novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. Int. J.
Mol. Sci. 2014, 15, 10567–10577. [CrossRef] [PubMed]
49. Gallagher, I.J.; Scheele, C.; Keller, P.; Nielsen, A.R.; Remenyi, J.; Fischer, C.P.; Roder, K.; Babraj, J.;
Wahlestedt, C.; Hutvagner, G. Integration of microRNA changes in vivo identifies novel molecular features
of muscle insulin resistance in type 2 diabetes. Genome Med. 2010, 2, 9. [CrossRef] [PubMed]
50. Klöting, N.; Berthold, S.; Kovacs, P.; Schön, M.R.; Fasshauer, M.; Ruschke, K.; Stumvoll, M.; Blüher, M.
MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS ONE 2009, 4, e4699.
[CrossRef] [PubMed]
51. Pan, J.; Chen, H. Expression of miR-155 and miR-146a in patients with type 2 diabetes mellitus and its
significance. Zhejiang Clin. Med. 2014, 16, 1042–1043.
Int. J. Mol. Sci. 2017, 18, 456 20 of 23
52. Yang, S.; Zhao, J.; Chen, Y.; Lei, M. Biomarkers associated with ischemic stroke in diabetes mellitus patients.
Cardiovasc. Toxicol. 2016, 16, 213–222. [CrossRef] [PubMed]
53. Yan, S.; Wang, T.; Huang, S.; Di, Y.; Huang, Y.; Liu, X.; Luo, Z.; Han, W.; An, B. Differential expression of
microRNAs in plasma of patients with prediabetes and newly diagnosed type 2 diabetes. Acta Diabetol. 2016,
53, 693–702. [CrossRef] [PubMed]
54. Wang, Y.; Li, J.Y.; Du, W.P.; Jin, W.B. Association analysis between plasma leptin, insulin levels and their
microRNA expression in patients with type 2 diabetes mellitus. Chin. J. Diabetes 2016, 24, 28–31.
55. Wang, C.; Wan, S.; Yang, T.; Niu, D.; Zhang, A.; Yang, C.; Cai, J.; Wu, J.; Song, J.; Zhang, C.Y.; et al. Increased
serum microRNAs are closely associated with the presence of microvascular complications in type 2 diabetes
mellitus. Sci. Rep. 2016, 6, 20032. [CrossRef] [PubMed]
56. Seyhan, A.A.; Nunez Lopez, Y.O.; Xie, H.; Yi, F.; Mathews, C.; Pasarica, M.; Pratley, R.E. Pancreas-enriched
miRNAs are altered in the circulation of subjects with diabetes: A pilot cross-sectional study. Sci. Rep. 2016,
6, 31479. [CrossRef] [PubMed]
57. Rezk, N.A.; Sabbah, N.A.; Saad, M.S. Role of microRNA 126 in screening, diagnosis, and prognosis of
diabetic patients in Egypt. IUBMB Life 2016, 68, 452–458. [CrossRef] [PubMed]
58. Pek, S.L.; Sum, C.F.; Lin, M.X.; Cheng, A.K.; Wong, M.T.; Lim, S.C.; Tavintharan, S. Circulating and visceral
adipose miR-100 is down-regulated in patients with obesity and type 2 diabetes. Mol. Cell. Endocrinol. 2016,
427, 112–123. [CrossRef] [PubMed]
59. Li, M.Y.; Pan, S.R.; Qiu, A.Y. Roles of microRNA-221/222 in type 2 diabetic patients with post-menopausal
breast cancer. Genet. Mol. Res. 2016. [CrossRef] [PubMed]
60. Latouche, C.; Natoli, A.; Reddy-Luthmoodoo, M.; Heywood, S.E.; Armitage, J.A.; Kingwell, B.A.
MicroRNA-194 modulates glucose metabolism and its skeletal muscle expression is reduced in diabetes.
PLoS ONE 2016, 11, e0155108. [CrossRef] [PubMed]
61. Jansen, F.; Wang, H.; Przybilla, D.; Franklin, B.S.; Dolf, A.; Pfeifer, P.; Schmitz, T.; Flender, A.; Endl, E.;
Nickenig, G.; et al. Vascular endothelial microparticles-incorporated microRNAs are altered in patients with
diabetes mellitus. Cardiovasc. Diabetol. 2016, 15, 49. [CrossRef] [PubMed]
62. Hou, X.; Wu, W.; Yin, B.; Liu, X.; Ren, F. MicroRNA-463–3p/ABCG4: A new axis in glucose-stimulated
insulin secretion. Obesity 2016, 24, 2368–2376. [CrossRef] [PubMed]
63. Ding, L.; Ai, D.; Wu, R.; Zhang, T.; Jing, L.; Lu, J.; Zhong, L. Identification of the differential expression of
serum microRNA in type 2 diabetes. Biosci. Biotechnol. Biochem. 2016, 80, 461–465. [CrossRef] [PubMed]
64. Baldeon Rojas, L.; Weigelt, K.; de Wit, H.; Ozcan, B.; van Oudenaren, A.; Sempertegui, F.; Sijbrands, E.;
Grosse, L.; van Zonneveld, A.J.; Drexhage, H.A.; et al. Study on inflammation-related genes and microRNAs,
with special emphasis on the vascular repair factor HGF and miR-574-3p, in monocytes and serum of patients
with T2D. Diabetol. Metab. Syndr. 2016, 8, 6. [CrossRef] [PubMed]
65. Sebastiani, G.; Po, A.; Miele, E.; Ventriglia, G.; Ceccarelli, E.; Bugliani, M.; Marselli, L.; Marchetti, P.;
Gulino, A.; Ferretti, E.; et al. MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets
and negatively regulates insulin secretion. Acta Diabetol. 2015, 52, 523–530. [CrossRef] [PubMed]
66. Olivieri, F.; Spazzafumo, L.; Bonafe, M.; Recchioni, R.; Prattichizzo, F.; Marcheselli, F.; Micolucci, L.; Mensa, E.;
Giuliani, A.; Santini, G.; et al. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells:
Relationship with type 2 diabetes complications. Oncotarget 2015, 6, 35372–35382. [PubMed]
67. Long, Y.; Zhan, Q.; Yuan, M.; Duan, X.; Zhou, J.; Lu, J.; Li, Z.; Yu, F.; Zhou, X.; Yang, Q.; et al. The expression
of microRNA-223 and FAM5C in cerebral infarction patients with diabetes mellitus. Cardiovasc. Toxicol. 2017,
17, 42–48. [CrossRef] [PubMed]
68. Lenin, R.; Sankaramoorthy, A.; Mohan, V.; Balasubramanyam, M. Altered immunometabolism at the interface
of increased endoplasmic reticulum (ER) stress in patients with type 2 diabetes. J. Leukoc. Biol. 2015, 98,
615–622. [CrossRef] [PubMed]
69. Jiao, Y.; Zhu, M.; Mao, X.; Long, M.; Du, X.; Wu, Y.; Abudureyimu, K.; Zhang, C.; Wang, Y.; Tao, Y.; et al.
MicroRNA-130a expression is decreased in Xinjiang Uygur patients with type 2 diabetes mellitus. Am. J.
Transl. Res. 2015, 7, 1984–1991. [PubMed]
70. Higuchi, C.; Nakatsuka, A.; Eguchi, J.; Teshigawara, S.; Kanzaki, M.; Katayama, A.; Yamaguchi, S.;
Takahashi, N.; Murakami, K.; Ogawa, D.; et al. Identification of circulating miR-101, miR-375 and miR-802 as
biomarkers for type 2 diabetes. Metabolism 2015, 64, 489–497. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 456 21 of 23
71. Bao, L.; Fu, X.; Si, M.; Wang, Y.; Ma, R.; Ren, X.; Lv, H. MicroRNA-185 targets SOCS3 to inhibit β-cell
dysfunction in diabetes. PLoS ONE 2015, 10, e0116067. [CrossRef] [PubMed]
72. Baldeon Rojas, L.; Weigelt, K.; de Wit, H.; Ozcan, B.; van Oudenaren, A.; Sempertegui, F.; Sijbrands, E.;
Grosse, L.; van Zonneveld, A.J.; Drexhage, H.A.; et al. Type 2 diabetes monocyte microRNA and mRNA
expression: Dyslipidemia associates with increased differentiation-related genes but not inflammatory
activation. PLoS ONE 2015, 10, e0129421.
73. Al-Kafaji, G.; Al-Mahroos, G.; Alsayed, N.A.; Hasan, Z.A.; Nawaz, S.; Bakhiet, M. Peripheral blood
microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes. Mol. Med. Rep.
2015, 12, 7485–7490. [CrossRef] [PubMed]
74. Kong, L.; Han, W.X.; Jiang, X.Y.; AXu, J.; Zhang, X.; Li, Q.; Guan, Q.B.; Gao, L.; Zhao, J.J. Expression and
clinical significance of peripheral miR-34a during the onset of type 2 diabetes. J. Shandong Univ. 2010, 48, 1–3.
75. Liang, G.W.; Song, Y.; Shao, D.H.; Xu, X.; He, M.L. The change of serum miR-375 and miR-29a and their
correlation with glycemic control and lipid profile in patients with newly diagnosed type 2 diabete. Chin. J.
Lab. Diagn. 2013, 17, 475–478.
76. Lu, S.Y.; Lu, Z.H.; Tan, L.; Wan, S. Association of Plasma miR-375 and miR-126 in patients with type 2
diabetes mellitus. J. Mod. Lab. Med. 2014, 29, 18–21.
77. Ortega, F.J.; Mercader, J.M.; Moreno-Navarrete, J.M.; Rovira, O.; Guerra, E.; Esteve, E.; Xifra, G.; Martinez, C.;
Ricart, W.; Rieusset, J.; et al. Profiling of circulating microRNAs reveals common microRNAs linked to type
2 diabetes that change with insulin sensitization. Diabetes Care 2014, 37, 1375–1383. [CrossRef] [PubMed]
78. Wang, X.; Sundquist, J.; Zoller, B.; Memon, A.A.; Palmer, K.; Sundquist, K.; Bennet, L. Determination of 14
circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS ONE 2014,
9, e86792. [CrossRef] [PubMed]
79. Wu, B.; Liu, W.-W.; HE, Y.; Hu, Y.S.; Zhang, Z.L. Analysis on related metabolic influencing factors for miR-21
expression levels in type 2 diabetic patients. Mod. Prev. Med. 2015, 42, 2218–2222.
80. Yan, S.T.; Li, C.L.; Tian, H.; Li, J.; Pei, Y.; Liu, Y.; Gong, Y.P.; Fang, F.S.; Sun, B.R. MiR-199a is overexpressed in
plasma of type 2 diabetes patients which contributes to type 2 diabetes by targeting GLUT4. Mol. Cell. Biochem.
2014, 397, 45–51. [CrossRef] [PubMed]
81. Zhou, B.; Li, C.; Qi, W.; Zhang, Y.; Zhang, F.; Wu, J.X.; Hu, Y.N.; Wu, D.M.; Liu, Y.; Yan, T.T.; et al.
Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity.
Diabetologia 2012, 55, 2032–2043. [CrossRef] [PubMed]
82. Berends, L.; Ozanne, S. Early determinants of type-2 diabetes. Best Pract. Res. Clin. Endocrinol. Metabol. 2012,
26, 569–580. [CrossRef] [PubMed]
83. Lorenzen, J.; Kumarswamy, R.; Dangwal, S.; Thum, T. MicroRNAs in diabetes and diabetes-associated
complications. RNA Biol. 2012, 9, 820–827. [CrossRef] [PubMed]
84. Dehwah, M.A.S.; Xu, A.; Huang, Q. MicroRNAs and type 2 diabetes/obesity. J. Genet. Genom. 2012, 39,
11–18. [CrossRef] [PubMed]
85. Rome, S. Are extracellular microRNAs involved in type 2 diabetes and related pathologies? Clin. Biochem.
2013, 46, 937–945. [CrossRef] [PubMed]
86. Pansuria, M.; Xi, H.; Li, L.; Yang, X.-F.; Wang, H. Insulin resistance, metabolic stress, and atherosclerosis.
Front. Biosci. 2012, 4, 916–931.
87. Poy, M.N.; Eliasson, L.; Krutzfeldt, J.; Kuwajima, S.; Ma, X.; MacDonald, P.E.; Pfeffer, S.; Tuschl, T.;
Rajewsky, N.; Rorsman, P. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004, 432,
226–230. [CrossRef] [PubMed]
88. Hashimoto, N.; Kido, Y.; Uchida, T.; Asahara, S.-I.; Shigeyama, Y.; Matsuda, T.; Takeda, A.; Tsuchihashi, D.;
Nishizawa, A.; Ogawa, W. Ablation of PDK1 in pancreatic β-cells induces diabetes as a result of loss of β-cell
mass. Nat. Genet. 2006, 38, 589–593. [CrossRef] [PubMed]
89. Gilbert, E.R.; Liu, D. Epigenetics: The missing link to understanding β-cell dysfunction in the pathogenesis
of type 2 diabetes. Epigenetics 2012, 7, 841–852. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 456 22 of 23
90. Plaisance, V.; Waeber, G.; Regazzi, R.; Abderrahmani, A. Role of microRNAs in Islet β-cell compensation and
failure during diabetes. J. Diabetes Res. 2014, 2014, 618652. [CrossRef] [PubMed]
91. Nesca, V.; Guay, C.; Jacovetti, C.; Menoud, V.; Peyot, M.-L.; Laybutt, D.R.; Prentki, M.; Regazzi, R.
Identification of particular groups of microRNAs that positively or negatively impact on β-cell function in
obese models of type 2 diabetes. Diabetologia 2013, 56, 2203–2212. [CrossRef] [PubMed]
92. Sacco, J.; Adeli, K. MicroRNAs: Emerging roles in lipid and lipoprotein metabolism. Curr. Opin. Lipidol.
2012, 23, 220–225. [CrossRef] [PubMed]
93. Williams, M.D.; Mitchell, G.M. MicroRNAs in insulin resistance and obesity. Exp. Diabetes Res. 2012,
2012, 484696. [CrossRef] [PubMed]
94. Karbiener, M.; Fischer, C.; Nowitsch, S.; Opriessnig, P.; Papak, C.; Ailhaud, G.; Dani, C.; Amri, E.-Z.;
Scheideler, M. MicroRNA miR-27b impairs human adipocyte differentiation and targets PPARγ.
Biochem. Biophys. Res. Commun. 2009, 390, 247–251. [CrossRef] [PubMed]
95. Peng, Y.; Yu, S.; Li, H.; Xiang, H.; Peng, J.; Jiang, S. MicroRNAs: Emerging roles in adipogenesis and obesity.
Cell. Signal. 2014, 26, 1888–1896. [CrossRef] [PubMed]
96. Hamar, P. Role of regulatory microRNAs in type 2 diabetes mellitus-related inflammation. Nucleic Acid Ther.
2012, 22, 289–294. [PubMed]
97. Keren, A.; Tamir, Y.; Bengal, E. The p38 MAPK signaling pathway: A major regulator of skeletal muscle
development. Mol. Cell. Endocrinol. 2006, 252, 224–230. [CrossRef] [PubMed]
98. Song, M.-Y.; Pan, K.-F.; Su, H.-J.; Zhang, L.; Ma, J.-L.; Li, J.-Y.; Yuasa, Y.; Kang, D.; Kim, Y.S.; You, W.-C.
Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer.
PLoS ONE 2012, 7, e33608. [CrossRef] [PubMed]
99. Pan, F.; You, J.; Liu, Y.; Qiu, X.; Yu, W.; Ma, J.; Pan, L.; Zhang, A.; Zhang, Q. Differentially expressed
microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile
dysfunction. Mol. Genet. Genom. 2016, 291, 2215–2224. [CrossRef] [PubMed]
100. He, J.S.; Lian, C.W.; Fang, Y.L.; Wu, J.Z.; Ye, X.L.; Zhu, S.B. Influence and significance of intervening diabetes
microRNA expression profile of NOD mice with exendin-4. Eur Rev. Med. Pharmacol. Sci. 2016, 20, 4322–4327.
[PubMed]
101. Singh, G.B.; Raut, S.K.; Khanna, S.; Kumar, A.; Sharma, S.; Prasad, R.; Khullar, M. MicroRNA-200c modulates
DUSP-1 expression in diabetes-induced cardiac hypertrophy. Mol. Cell. Biochem. 2016, 424, 1–11. [CrossRef]
[PubMed]
102. Wei, S.; Zhang, M.; Yu, Y.; Xue, H.; Lan, X.; Liu, S.; Hatch, G.; Chen, L. HNF-4α regulated miR-122
contributes to development of gluconeogenesis and lipid metabolism disorders in type 2 diabetic mice and
in palmitate-treated HepG2 cells. Eur. J. Pharmacol. 2016, 791, 254–263. [CrossRef] [PubMed]
103. Chen, H.Y.; Zhong, X.; Huang, X.R.; Meng, X.M.; You, Y.; Chung, A.C.; Lan, H.Y. MicroRNA-29b inhibits
diabetic nephropathy in db/db mice. Mol. Ther. 2014, 22, 842–853. [CrossRef] [PubMed]
104. Guay, C.; Regazzi, R. Role of islet microRNAs in diabetes: Which model for which question? Diabetologia
2015, 58, 456–463. [CrossRef] [PubMed]
105. Huang, B.; Qin, W.; Zhao, B.; Shi, Y.; Yao, C.; Li, J.; Xiao, H.; Jin, Y. MicroRNA expression profiling in diabetic
GK rat model. Acta Biochim. Biophys. Sin. 2009, 41, 472–477. [CrossRef] [PubMed]
106. Lu, T.P.; Lee, C.Y.; Tsai, M.H.; Chiu, Y.C.; Hsiao, C.K.; Lai, L.C.; Chuang, E.Y. MiRSystem: An integrated
system for characterizing enriched functions and pathways of microRNA targets. PLoS ONE 2012, 7, e42390.
[CrossRef] [PubMed]
107. Cho, S.; Jang, I.; Jun, Y.; Yoon, S.; Ko, M.; Kwon, Y.; Choi, I.; Chang, H.; Ryu, D.; Lee, B.; et al. MiRGator v3.0:
A microRNA portal for deep sequencing, expression profiling and mRNA targeting. Nucleic Acids Res. 2013,
41, 252–257. [CrossRef] [PubMed]
108. Backes, C.; Kehl, T.; Stockel, D.; Fehlmann, T.; Schneider, L.; Meese, E.; Lenhof, H.P.; Keller, A. MiRPathDB:
A new dictionary on microRNAs and target pathways. Nucleic Acids Res. 2017, 45, D90–D96. [CrossRef]
[PubMed]
109. Palmer, J.D.; Soule, B.P.; Simone, B.A.; Zaorsky, N.G.; Jin, L.; Simone, N.L. MicroRNA expression altered by
diet: Can food be medicinal? Ageing Res. Rev. 2014, 17, 16–24. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 456 23 of 23
110. Chen, G.Q.; Lian, W.J.; Wang, G.M.; Wang, S.; Yang, Y.Q.; Zhao, Z.W. Altered microRNA expression in
skeletal muscle results from high-fat diet-induced insulin resistance in mice. Mol. Med. Rep. 2012, 5,
1362–1368. [PubMed]
111. Baier, S.R.; Nguyen, C.; Xie, F.; Wood, J.R.; Zempleni, J. MicroRNAs are absorbed in biologically meaningful
amounts from nutritionally relevant doses of cow milk and affect gene expression in peripheral blood
mononuclear cells, HEK-293 kidney cell cultures, and mouse livers. J. Nutr. 2014, 144, 1495–1500. [CrossRef]
[PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
